Compare PTGX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | LMAT |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 2.1B |
| IPO Year | 2016 | 2006 |
| Metric | PTGX | LMAT |
|---|---|---|
| Price | $142.25 | $81.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $108.23 | $105.80 |
| AVG Volume (30 Days) | ★ 526.9K | 205.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | ★ 2.35 | 1.42 |
| Revenue | N/A | ★ $249,602,000.00 |
| Revenue This Year | $874.25 | $14.21 |
| Revenue Next Year | N/A | $8.88 |
| P/E Ratio | $58.44 | ★ $56.92 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $62.24 | $78.22 |
| 52 Week High | $160.81 | $118.01 |
| Indicator | PTGX | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 49.71 |
| Support Level | $141.95 | $78.65 |
| Resistance Level | $151.24 | $82.45 |
| Average True Range (ATR) | 5.11 | 1.61 |
| MACD | -0.89 | 0.62 |
| Stochastic Oscillator | 48.37 | 95.63 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.